PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

Laure Hirsch; Laurence Zitvogel; Alexander Eggermont; Aurelien Marabelle

doi:10.1038/s41416-018-0294-4

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

Br J Cancer. 2019 Jan;120(1):3-5. doi: 10.1038/s41416-018-0294-4. Epub 2018 Nov 9.

Authors

Laure Hirsch¹, Laurence Zitvogel², Alexander Eggermont³, Aurelien Marabelle^{4

5}

Affiliations

¹ Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France.
² Gustave Roussy, Université Paris-Saclay, INSERM U1015, Villejuif, F-94805, France.
³ Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France.
⁴ Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France. [email protected].
⁵ Gustave Roussy, Université Paris-Saclay, INSERM U1015, Villejuif, F-94805, France. [email protected].

Abstract

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / immunology
Antibodies, Monoclonal / therapeutic use
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / immunology*
Clinical Trials as Topic
Humans
Immunotherapy*
Neoplasms / classification
Neoplasms / genetics
Neoplasms / immunology
Neoplasms / therapy*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology*
Signal Transduction

Substances

Antibodies, Monoclonal
B7-H1 Antigen
CD274 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor